{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:51:10Z","timestamp":1790682670204,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115565"],"award-info":[{"award-number":["115565"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU14\/03992"],"award-info":[{"award-number":["FPU14\/03992"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jpba.2019.112999","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T21:24:36Z","timestamp":1574198676000},"page":"112999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Discovering new metabolite alterations in primary sj\u00f6gren\u2019s syndrome in urinary and plasma samples using an HPLC-ESI-QTOF-MS methodology"],"prefix":"10.1016","volume":"179","author":[{"given":"\u00c1lvaro","family":"Fern\u00e1ndez-Ochoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Borr\u00e1s-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Quirantes-Pin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta E.","family":"Alarc\u00f3n-Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Segura-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.112999_bib0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12016-007-8011-8","article-title":"T Lymphocytes in Sj\u00f6gren\u2019s Syndrome: Contributors to and Regulators of Pathophysiology","volume":"32","author":"Katsifis","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jpba.2019.112999_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5584\/jiomics.v2i2.97","article-title":"Integrated omics analysis of sjogren\u2019s syndrome","volume":"2","author":"Ai","year":"2012","journal-title":"J. Integr. OMICS"},{"key":"10.1016\/j.jpba.2019.112999_bib0015","first-page":"4","article-title":"Metabolomics - an overview. From basic principles to potential biomarkers (part 1)","volume":"40","author":"Agin","year":"2016","journal-title":"Med. Nucl."},{"key":"10.1016\/j.jpba.2019.112999_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159384","article-title":"Metabolic profiling of systemic lupus erythematosus and comparison with primary Sj\u00f6gren\u2019s syndrome and systemic sclerosis","volume":"11","author":"Bengtsson","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2019.112999_bib0025","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-018-4021-6","article-title":"LC-MS-based serum metabolomics reveals a distinctive signature in patients with rheumatoid arthritis","volume":"37","author":"Li","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jpba.2019.112999_bib0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12683","article-title":"Metabolomics analysis of saliva from patients with primary Sj\u00f6gren\u2019s syndrome","volume":"182","author":"Kageyama","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jpba.2019.112999_bib0035","article-title":"Metabolic profiling of saliva in patients with primary Sj?gren?s syndrome","volume":"03","author":"Mikkonen","year":"2013","journal-title":"J. Postgenomics Drug Biomark. Dev."},{"key":"10.1016\/j.jpba.2019.112999_bib0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4939-2377-9_13","article-title":"The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research","volume":"1277","author":"Emwas","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2019.112999_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073076","article-title":"The human urine metabolome","volume":"8","author":"Bouatra","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2019.112999_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-016-0681-8","article-title":"Urine metabolome profiling of immune-mediated inflammatory diseases","volume":"14","author":"Alonso","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.jpba.2019.112999_bib0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chroma.2015.12.056","article-title":"Use of a pre-analysis osmolality normalisation method to correct for variable urine concentrations and for improved metabolomic analyses","volume":"1431","author":"Chetwynd","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.112999_bib0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2018.09.021","article-title":"Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients","volume":"162","author":"Fern\u00e1ndez-Ochoa","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112999_bib0065","doi-asserted-by":"crossref","DOI":"10.1002\/cpbi.11","article-title":"Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis","volume":"55","author":"Xia","year":"2016","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"10.1016\/j.jpba.2019.112999_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11306-007-0099-6","article-title":"Assessment of PLSDA cross validation","volume":"4","author":"Westerhuis","year":"2008","journal-title":"Metabolomics"},{"key":"10.1016\/j.jpba.2019.112999_bib0075","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/14737175.2015.1049999","article-title":"What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?","volume":"15","author":"Davis","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jpba.2019.112999_bib0080","first-page":"1688","article-title":"Association of increased treg cell levels with elevated indoleamine 2,3-Dioxygenase activity and an imbalanced kynurenine pathway in Interferon-Positive primary sj\u00f6gren\u2019s syndrome","volume":"68","author":"Maria","year":"2016","journal-title":"."},{"key":"10.1016\/j.jpba.2019.112999_bib0085","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","article-title":"Gut microbiota regulation of tryptophan metabolism in health and disease","volume":"23","author":"Agus","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jpba.2019.112999_bib0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jpba.2019.112999_bib0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3390\/ijms18040836","article-title":"Potential role of free fatty acids in the pathogenesis of periodontitis and primary sj\u00f6gren\u2019s syndrome","volume":"18","author":"Shikama","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2019.112999_bib0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/07315724.2002.10719248","article-title":"Omega-3 fatty acids in inflammation and autoimmune diseases","volume":"21","author":"Simopoulos","year":"2002","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.jpba.2019.112999_bib0105","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0731-7085(99)00235-6","article-title":"Quantitative analysis of urinary acylglycines for the diagnosis of \u03b2-oxidation defects using GC-NCI-MS","volume":"21","author":"Costa","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112999_bib0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-2952(02)01179-6","article-title":"Lysophosphatidylcholine as a ligand for immunoregulation","volume":"64","author":"Kabarowski","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2019.112999_bib0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jpba.2019.112999_bib0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/096120399678847434","article-title":"Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE","volume":"8","author":"Wu","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.jpba.2019.112999_bib0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-016-0552-3","article-title":"Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study","volume":"14","author":"K\u00fchn","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.jpba.2019.112999_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041456","article-title":"Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes","volume":"7","author":"Barber","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2019.112999_bib0135","article-title":"High prevalence of serum metabolic alterations in primary Sj\u00f6gren\u2019s syndrome: Influence on clinical and immunological expression","author":"Ramos-Casals","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jpba.2019.112999_bib0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/ard.59.5.321","article-title":"Inflammation-mediated rheumatic diseases and atherosclerosis","author":"Manzi","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jpba.2019.112999_bib0145","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1039\/c2mb25022e","article-title":"Plasma metabonomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry","volume":"8","author":"Gu","year":"2012","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.jpba.2019.112999_bib0150","first-page":"1","article-title":"Rapid resolution liquid chromatography coupled with quadrupole time-of-flight mass spectrometry-based metabolomics approach to study the effects of jieduquyuziyin prescription on systemic lupus erythematosus","volume":"9","author":"Ding","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519319004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519319004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:02:02Z","timestamp":1760000522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519319004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"alternative-id":["S0731708519319004"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112999","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovering new metabolite alterations in primary sj\u00f6gren\u2019s syndrome in urinary and plasma samples using an HPLC-ESI-QTOF-MS methodology","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112999"}}